Shire Sues to Stop Roche From Launching Competing Hemophilia Drug

Shire is trying to stop Roche from launching a competing hemophilia drug by asserting patent infringement litigation (Baxalta, Inc. v. Genentech, Inc., D. Del., 1:17-cv-509, filed 5/4/17).

The complaint filed in the U.S. District Court for the District of Delaware by Shire’s Baxalta Inc. alleged that Genentech, a division of Roche, and Japan-based Chugai Pharmaceutical Co. plan to bring the drug emicizumab to the U.S. market by the end of the year. Baxalta’s patent covers an antibody that initiates coagulation to stop bleeding in individuals whose bodies lack the factors that automatically begin the process. Emicizumab is ...